Multimodal AI predicts clinical outcomes of drug combinations from preclinical data

• URL: http://arxiv.org/abs/2503.02781v1
• Date: Tue, 04 Mar 2025 16:55:14 GMT
• Title: Multimodal AI predicts clinical outcomes of drug combinations from preclinical data
• Authors: Yepeng Huang, Xiaorui Su, Varun Ullanat, Ivy Liang, Lindsay Clegg, Damilola Olabode, Nicholas Ho, Bino John, Megan Gibbs, Marinka Zitnik,
• Abstract summary: We introduce MADRIGAL, a multimodal AI model that learns from structural, pathway, cell viability, and transcriptomic data.<n>It predicts drug combination effects across 953 clinical outcomes and 21842 compounds, including combinations of approved drugs and novel compounds in development.<n>It outperforms single-modality methods and state-of-the-art models in predicting adverse drug interactions.
• Score: 7.522186980639714
• License: http://arxiv.org/licenses/nonexclusive-distrib/1.0/
• Abstract: Predicting clinical outcomes from preclinical data is essential for identifying safe and effective drug combinations. Current models rely on structural or target-based features to identify high-efficacy, low-toxicity drug combinations. However, these approaches fail to incorporate the multimodal data necessary for accurate, clinically-relevant predictions. Here, we introduce MADRIGAL, a multimodal AI model that learns from structural, pathway, cell viability, and transcriptomic data to predict drug combination effects across 953 clinical outcomes and 21842 compounds, including combinations of approved drugs and novel compounds in development. MADRIGAL uses a transformer bottleneck module to unify preclinical drug data modalities while handling missing data during training and inference--a major challenge in multimodal learning. It outperforms single-modality methods and state-of-the-art models in predicting adverse drug interactions. MADRIGAL performs virtual screening of anticancer drug combinations and supports polypharmacy management for type II diabetes and metabolic dysfunction-associated steatohepatitis (MASH). It identifies transporter-mediated drug interactions. MADRIGAL predicts resmetirom, the first and only FDA-approved drug for MASH, among therapies with the most favorable safety profile. It supports personalized cancer therapy by integrating genomic profiles from cancer patients. Using primary acute myeloid leukemia samples and patient-derived xenograft models, it predicts the efficacy of personalized drug combinations. Integrating MADRIGAL with a large language model allows users to describe clinical outcomes in natural language, improving safety assessment by identifying potential adverse interactions and toxicity risks. MADRIGAL provides a multimodal approach for designing combination therapies with improved predictive accuracy and clinical relevance.

Related papers

• Continually Evolved Multimodal Foundation Models for Cancer Prognosis [50.43145292874533]
  Cancer prognosis is a critical task that involves predicting patient outcomes and survival rates.<n>Previous studies have integrated diverse data modalities, such as clinical notes, medical images, and genomic data, leveraging their complementary information.<n>Existing approaches face two major limitations. First, they struggle to incorporate newly arrived data with varying distributions into training, such as patient records from different hospitals.<n>Second, most multimodal integration methods rely on simplistic concatenation or task-specific pipelines, which fail to capture the complex interdependencies across modalities.
  arXiv  Detail & Related papers  (2025-01-30T06:49:57Z)
• MD-Syn: Synergistic drug combination prediction based on the multidimensional feature fusion method and attention mechanisms [0.0]
  Drug combination therapies have shown promising therapeutic efficacy in complex diseases and have demonstrated the potential to reduce drug resistance. The huge number of possible drug combinations makes it difficult to screen them all in traditional experiments. In this study, we proposed MD-Syn, a computational framework, which is based on the multidimensional feature fusion method and multi-head attention mechanisms.
  arXiv  Detail & Related papers  (2025-01-14T06:50:56Z)
• KITE-DDI: A Knowledge graph Integrated Transformer Model for accurately predicting Drug-Drug Interaction Events from Drug SMILES and Biomedical Knowledge Graph [0.11049608786515838]
  Drug-Drug Interactions (DDI) can cause significant bodily injury and even death.<n>Most contemporary research for predicting DDI events relies on either information from Biomedical Knowledge graphs (KG) or drug SMILES.<n>In this study, we propose a KG-integrated Transformer architecture to generate an end-to-end fully automated Machine Learning pipeline.
  arXiv  Detail & Related papers  (2024-12-08T00:49:57Z)
• Causal machine learning for predicting treatment outcomes [75.13093479526151]
  Causal machine learning (ML) offers flexible, data-driven methods for predicting treatment outcomes. Key benefit of causal ML is that it allows for estimating individualized treatment effects.
  arXiv  Detail & Related papers  (2024-10-11T12:39:08Z)
• A Cross-Field Fusion Strategy for Drug-Target Interaction Prediction [85.2792480737546]
  Existing methods fail to utilize global protein information during DTI prediction. Cross-field information fusion strategy is employed to acquire local and global protein information. Siamese drug-target interaction SiamDTI prediction method achieves higher accuracy levels than other state-of-the-art (SOTA) methods on novel drugs and targets.
  arXiv  Detail & Related papers  (2024-05-23T13:25:20Z)
• Enhancing drug and cell line representations via contrastive learning for improved anti-cancer drug prioritization [0.7070726553564699]
  We propose the use of contrastive learning to improve learned drug and cell line representations. We find that our learned representations exhibit a more balances reliance on drug- and cell line-derived features when making predictions.
  arXiv  Detail & Related papers  (2023-10-20T04:18:47Z)
• Drug Interaction Vectors Neural Network: DrIVeNN [0.7624669864625037]
  Polypharmacy is the concurrent use of multiple drugs to treat a single condition. Many serious ADEs associated with polypharmacy only become known after the drugs are in use. It is impractical to test every possible drug combination during clinical trials.
  arXiv  Detail & Related papers  (2023-08-26T14:24:41Z)
• Drug Synergistic Combinations Predictions via Large-Scale Pre-Training and Graph Structure Learning [82.93806087715507]
  Drug combination therapy is a well-established strategy for disease treatment with better effectiveness and less safety degradation. Deep learning models have emerged as an efficient way to discover synergistic combinations. Our framework achieves state-of-the-art results in comparison with other deep learning-based methods.
  arXiv  Detail & Related papers  (2023-01-14T15:07:43Z)
• SSM-DTA: Breaking the Barriers of Data Scarcity in Drug-Target Affinity Prediction [127.43571146741984]
  Drug-Target Affinity (DTA) is of vital importance in early-stage drug discovery. wet experiments remain the most reliable method, but they are time-consuming and resource-intensive. Existing methods have primarily focused on developing techniques based on the available DTA data, without adequately addressing the data scarcity issue. We present the SSM-DTA framework, which incorporates three simple yet highly effective strategies.
  arXiv  Detail & Related papers  (2022-06-20T14:53:25Z)
• Learning for Dose Allocation in Adaptive Clinical Trials with Safety Constraints [84.09488581365484]
  Phase I dose-finding trials are increasingly challenging as the relationship between efficacy and toxicity of new compounds becomes more complex. Most commonly used methods in practice focus on identifying a Maximum Tolerated Dose (MTD) by learning only from toxicity events. We present a novel adaptive clinical trial methodology that aims at maximizing the cumulative efficacies while satisfying the toxicity safety constraint with high probability.
  arXiv  Detail & Related papers  (2020-06-09T03:06:45Z)
• Reinforcement learning and Bayesian data assimilation for model-informed precision dosing in oncology [0.0]
  Current strategies comprise model-informed dosing tables or are based on maximum a-posteriori estimates. We propose three novel approaches for MIPD employing Bayesian data assimilation and/or reinforcement learning to control neutropenia. These approaches have the potential to substantially reduce the incidence of life-threatening grade 4 and subtherapeutic grade 0 neutropenia.
  arXiv  Detail & Related papers  (2020-06-01T16:38:27Z)

This list is automatically generated from the titles and abstracts of the papers in this site.

This site does not guarantee the quality of this site (including all information) and is not responsible for any consequences.